Cardinal Health Inc. stock (US14149Y1082): Dividend move and healthcare distribution in focus
Cardinal Health Inc. has declared a higher quarterly dividend, drawing investor attention to its role in the US healthcare distribution system. The company, a major distributor of pharmaceuticals and medical products, plays a critical role in the healthcare supply chain despite operating with relatively low margins. Its performance is influenced by demand for prescription drugs, the mix of branded and generic medicines, and hospital capital budgets.
A Look Back at Healthcare Providers & Services Stocks’ Q1 Earnings: McKesson (NYSE:MCK) Vs The Rest Of The Pack
This article reviews the Q1 earnings of several healthcare providers and services stocks, contrasting McKesson's performance with its peers. It highlights strong Q1 results for the sector generally, with agilon health as the top performer and Option Care Health as the weakest. The piece also briefly touches on broader market concerns, including the shift from AI anxiety to geopolitical risks.
Cardinal Health stock (US14149Y1082): focus on cost cuts and pharma growth after latest quarterly re
Cardinal Health recently reported quarterly figures, highlighting solid growth in its pharmaceutical distribution business and ongoing restructuring in its medical segment. The company is focusing on cost savings, capital allocation, and targeted investments to navigate pricing pressures and competition in the US healthcare supply chain. Investors are closely monitoring margin trends and capital returns as Cardinal Health works to balance growth with the challenges of a complex, regulated market.
Spotting Winners: Cardinal Health (NYSE:CAH) And Healthcare Providers & Services Stocks In Q1
This article analyzes Q1 performance for Cardinal Health (CAH) and other healthcare providers and services stocks. It highlights Cardinal Health's revenue miss but satisfactory quarter, agilon health (A AGL) as a top performer with significant stock growth, and Option Care Health (OPCH) as a weaker performer due to revenue shortfalls and guidance. The piece provides an overview of sector trends and individual company results.
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now
Cardinal Health (CAH) is recommended as a strong buy due to its expanding specialty portfolio, robust fiscal third-quarter results driven by pharmaceutical demand, and growth in theranostics and at-home solutions. The company's strong cash flow and disciplined capital allocation further strengthen its long-term earnings outlook, despite facing challenges like IRA pricing changes and a fragile recovery in its Global Medical Products and Distribution segment.
Spotting Winners: Cardinal Health (NYSE:CAH) And Healthcare Providers & Services Stocks In Q1
This article reviews the Q1 performance of Cardinal Health (NYSE:CAH) and other key players in the healthcare providers & services sector. It highlights Cardinal Health's steady performance, agilon health's strong Q1 as the sector's top performer, and Option Care Health's and Brookdale's weaker results. The piece also touches on shifts in market investor sentiment from AI concerns to geopolitical risks.
Spotting Winners: Cardinal Health (NYSE:CAH) And Healthcare Providers & Services Stocks In Q1
This article analyzes the Q1 performance of Cardinal Health (NYSE:CAH) and other key players in the healthcare providers & services sector. It highlights agilon health (NYSE:AGL) as the best performer and Option Care Health (NASDAQ:OPCH) as the weakest, providing revenue and stock performance details for each company. The report also touches on broader market concerns, including the shift from AI disruption anxieties to geopolitical risks related to the US conflict with Iran.
Cardinal Health Inc. stock (US14149Y1082): shares react to Q3 2026 earnings beat
Cardinal Health Inc. reported stronger-than-expected Q3 2026 earnings, posting $3.17 per share against an estimated $2.79, driving stock activity. The company's core business relies on pharmaceutical distribution and medical products supply across the US healthcare system. This earnings beat highlights its leverage in North American markets and its essential role as a healthcare infrastructure component for US investors, despite potential challenges from competitive pressures and regulatory changes.
Cardinal Health Inc. stock (US14149Y1082): steady gains and healthcare exposure for US investors
Cardinal Health Inc. (US14149Y1082) has seen recent stock price gains, highlighting its crucial role in the US healthcare supply chain as a major distributor of pharmaceuticals and medical products. The company's business model relies on high volumes and extensive logistics, serving various healthcare providers, with its growth prospects tied to broader trends like demographics and new therapies. While offering exposure to the core of the US healthcare infrastructure, investors should note its sensitivity to drug pricing, regulatory changes, and competitive pressures affecting its slim margins.
Is CAH Becoming the Backbone of US Healthcare Infrastructure?
Cardinal Health (CAH) is strategically positioning itself as a core component of the U.S. healthcare system, moving beyond mere distribution to become a critical infrastructure partner through its vast network and integrated services. The company's focus on operational reliability and comprehensive services in pharmaceutical distribution, specialty care, and advanced logistics is strengthening its role within the healthcare continuum. While CAH's stock performance has lagged its industry, it holds a Zacks Rank #2 (Buy) with positive earnings growth expectations, suggesting a robust outlook.
Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, U.S. jury finds
A U.S. jury found Japan-based Takeda Pharmaceutical liable for approximately $885 million in damages for orchestrating an anticompetitive scheme to delay the release of a generic version of its constipation drug, Amitiza. The lawsuit, part of a wave of "pay-for-delay" cases, concluded that Takeda's settlement with Par Pharmaceutical in 2014 illegally postponed generic competition, causing pharmacies, insurers, health funds, and retailers to overpay for the drug. This verdict marks the first time a jury has found a pharmaceutical company liable in class action litigation over such agreements, with potential damages tripling under U.S. antitrust law.
Integer Holdings Corporation (ITGR) Stock Analysis: Healthcare Innovator with 10% Upside Potential
Integer Holdings Corporation (ITGR), a medical device manufacturer with a market cap of $2.99 billion, presents an intriguing investment opportunity due to its robust market presence and a potential upside of 10.28% based on analyst projections. Despite a modest revenue growth of 0.50%, the company demonstrates solid financial performance with an EPS of 4.03 and ROE of 8.59%, backed by $98.1 million in free cash flow. Analysts have a favorable outlook, with six buy ratings and four hold ratings, indicating confidence in ITGR's strategic direction and market opportunities in the healthcare sector.
Cardinal Health stock (US14149Y1082): dividend hike and higher FY2026 outlook
Cardinal Health has increased its quarterly dividend and elevated its fiscal year 2026 earnings guidance, signaling strong momentum in its specialty pharmaceutical and distribution segments. This move, highlighted by a projected non-GAAP EPS of $10.70 to $10.80, reflects management's confidence in the company's cash generation and crucial role within the US healthcare system. While the dividend hike makes it attractive to income investors, the company still faces risks related to reimbursement pressures and supply-chain costs.
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRx stock rose after Humana announced Medicare Advantage coverage for its Barostim therapy, effective May 1, 2026. This policy expands patient access to the heart failure treatment and covers both FDA-approved indications and patients in the BENEFIT-HF trial. The news follows other favorable reimbursement developments earlier in 2026 and is expected to strengthen CVRx's commercial position and drive future revenue growth in the neuromodulation devices market.
Cardinal Health Inc. stock (US14149Y1082): dividend hike and higher FY2026 guidance in focus
Cardinal Health Inc. has announced a quarterly dividend increase and raised its fiscal year 2026 earnings guidance, driven by momentum in its specialty pharmaceutical business and distribution operations. The company, a major healthcare distributor, continues its long streak of annual dividend growth, a factor closely watched by income-oriented investors, while its updated outlook underscores confidence in future profitability. These developments position Cardinal Health as a stable investment within the US healthcare supply chain, balancing modest yield with potential for earnings growth.
Lone Peak Global Investors Liquidates Entire Thermon Group Position in Q1 2026 - News and Statistics
Lone Peak Global Investors has fully divested its stake in Thermon Group in Q1 2026, selling approximately 430,230 shares valued at $20.05 million. This decision follows a 120% surge in Thermon's stock over the past year, significantly outperforming the S&P 500's 25% increase. Despite Thermon's strong financial performance and growth in AI infrastructure and industrial electrification, the fund opted to reallocate capital after substantial gains.
Lone Peak Global Investors Discloses $24M KBR Stake in SEC Filing - News and Statistics
Lone Peak Global Investors has acquired a new stake in KBR, purchasing 584,372 shares valued at approximately $24.00 million. This investment, representing 3.59% of Lone Peak's reportable assets, indicates a belief that the market undervalues KBR, especially considering its planned breakup and government-focused contracts. Despite KBR's recent stock underperformance and a Q1 revenue decline, the company maintains a strong backlog and continues to secure significant contracts in defense, AI, and energy transition, with a tax-free spin-off planned for its Mission Technology Solutions business.
What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings
Lone Peak Global Investors fully exited its position in Thermon Group (NYSE:THR), selling approximately 430,230 shares for an estimated $20.05 million. This divestment occurred after Thermon's stock surged 120% over the past year and the company reported record quarterly revenue and bookings, raising questions about whether investors are rotating capital despite strong underlying business momentum. Thermon specializes in industrial process heating solutions and is experiencing accelerated demand linked to data centers, electrification, LNG, and power infrastructure.
Cardinal Health (CAH) Is Up 6.3% After Raising 2026 EPS Outlook and Trimming Tax Guidance
Cardinal Health recently raised its fiscal year 2026 non-GAAP EPS outlook and lowered its expected effective tax rate following mixed-to-positive third-quarter results. The company also declared a quarterly dividend of US$0.5158 per share. This positive news highlights the strength of its Pharmaceutical & Specialty Solutions segment, driven by specialty drug demand, but the article also notes ongoing concerns regarding valuation and potential pressure from regulatory conditions.
Analysts Are Bullish on Top Technology Stocks: Zeta Global Holdings Corp (ZETA), Infineon Technologies AG (IFNNF)
This article highlights bullish analyst ratings for Zeta Global Holdings Corp (ZETA) and Infineon Technologies AG (IFNNF). Needham analyst Scott Berg maintained a Buy rating on ZETA with a $25.00 price target, and Goldman Sachs analyst Alexander Duval reiterated a Buy rating on IFNNF with a EUR75.00 price target. The consensus for both stocks is a Strong Buy, with significant upside potential.
Is It Time To Revisit Cencora (COR) After The Recent Share Price Slump?
Cencora (COR) has experienced a recent share price slump, but Simply Wall St's valuation checks indicate it is currently undervalued. Both a Discounted Cash Flow (DCF) analysis and a Price-to-Earnings (P/E) ratio comparison suggest the stock is undervalued, with the DCF model estimating its intrinsic value at $486.69 per share, significantly above its current price of approximately $257.71. The article encourages investors to analyze Cencora's narrative and future prospects further, considering a range of perspectives on its revenue and earnings growth.
A Look At Henry Schein (HSIC) Valuation After Solid Q1 Update And Reaffirmed Guidance
Henry Schein (HSIC) is currently trading at a discount to its estimated intrinsic value and analyst targets despite solid Q1 results and reaffirmed guidance. The company's focus on high-margin businesses like Specialty Products and Technology is expected to drive earnings growth, contributing to a "fair value" narrative of $90.21 per share. However, potential risks such as competitive pricing or regulatory setbacks could challenge this optimistic outlook.
Cardinal Health (CAH) Is Up 6.3% After Raising 2026 EPS Outlook and Trimming Tax Guidance
Cardinal Health (CAH) recently announced a quarterly dividend and increased its fiscal 2026 non-GAAP EPS outlook while lowering its expected effective tax rate following strong third-quarter results, particularly from its Pharmaceutical & Specialty Solutions segment. This positive news, driven by strong specialty drug demand, reinforces earnings momentum as a key short-term driver, though valuation concerns and potential regulatory pressures remain. The company's narrative projects significant revenue and earnings growth by 2029, suggesting a 26% upside to its current price according to Simply Wall St's fair value assessment.
Cardinal Health (CAH) Is Up 6.3% After Raising 2026 EPS Outlook and Trimming Tax Guidance
Cardinal Health (CAH) stock rose by 6.3% after the company raised its full-year fiscal 2026 non-GAAP EPS outlook and lowered its effective tax rate, following mixed-to-positive third-quarter results. The company also declared a quarterly dividend. This stronger outlook is primarily driven by its Pharmaceutical & Specialty Solutions segment, which benefits from strong specialty drug demand and expanding partnerships.
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband Inc., through its Active Intelligence subsidiary, announced its participation in the June 2026 ECRM conference to showcase its expanding AI wellness product portfolio and new product launches. The company plans to meet with major retailers like Walmart, Walgreens, Amazon, and Cardinal Health to introduce AI Performance Tape, AI Energy Patches, and AI Sleep, aiming to broaden its national retail presence in the rapidly growing wellness market. This move highlights Nutriband's strategy to capitalize on increasing consumer demand for wellness, recovery, and performance solutions.
Lowe's Companies Among 7 Companies To Announce Dividend Increases In The Second Half Of May
Lowe's Companies is expected to announce its 64th consecutive annual dividend increase in late May, despite facing EPS stagnation. The dividend growth is predicted to be between 3.3% and 4.2%, with a forward yield around 2.27%–2.29%. Other companies like Donaldson Company are also anticipated to announce dividend increases, while Flowers Foods faces challenges regarding its payout sustainability due to declining earnings.
Lowe’s Companies Stock Among 7 Companies To Announce Dividend Increases In Second Half May
Lowe's Companies (LOW) is expected to announce its 64th consecutive annual dividend increase in late May, despite stagnant EPS, with a projected 3.3–4.2% increase. The company is strategically shifting focus to professional customers and made two acquisitions in 2025 to drive growth amidst flat EPS guidance for 2026. Other companies like Donaldson Company are also anticipated to raise dividends, while Flowers Foods faces challenges due to declining earnings impacting dividend sustainability.
Do options traders know something about Cardinal Health stock we don't?
This article from MSN discusses whether options trading activity in Cardinal Health (CAH) stock might indicate insights not yet apparent to the general market. It suggests that unusual options movements can sometimes signal upcoming stock price changes.
Cardinal Health Inc. stock (US14149Y1082): EPS beat contrasts with recent share-price weakness
Cardinal Health Inc. reported stronger-than-expected fiscal Q3 2026 earnings, topping consensus estimates and raising its full-year EPS guidance. Despite this positive financial performance and an improved technical signal with the stock climbing above its 200-day moving average, the company's shares have experienced recent weakness, lagging behind some healthcare peers. This divergence suggests investors are weighing fundamental improvements against market sentiment and the performance of other healthcare segments like managed care.
Nutriband brings AI wellness tapes and energy patches to Walmart talks
Nutriband (NASDAQ: NTRB) and its Active Intelligence subsidiary will showcase an expanding AI wellness product portfolio, including new AI Performance Tape, AI Energy Patches, and AI Sleep products, at the June 2026 ECRM conference. The company is set to meet with major retailers like Walmart, Walgreens, Amazon, and Cardinal Health to discuss distribution, building on recent international approvals for its AI kinesiology tapes. This move reinforces Nutriband's strategy to commercialize its AI-branded wellness products alongside the development of its AVERSA abuse-deterrent transdermal technology.
Limoneira Co - Common Stock (NQ: LMNR)
This article provides recent news headlines related to Limoneira Co (LMNR), highlighting its strategic shift towards avocado production, investments in organic recycling, and exploration of new housing initiatives. Key news includes the completion of a joint venture, pausing of common stock dividends for strategic investments, and mixed quarterly results during this transition period. The company has also reported on various earnings calls and financial results, indicating a focus away from lemons to avocados for future growth.
Cardinal Health Inc. stock (US14149Y1082): earnings beat meets fresh momentum signal
Cardinal Health Inc. reported a strong Q3 2026 earnings beat, exceeding analyst expectations, and subsequently raised its full-year guidance, signaling improved profitability and management confidence. Concurrently, the company's stock recaptured its 200-day moving average, a key technical indicator often interpreted as a sign of improving momentum. While these factors present a positive outlook for investors, the healthcare distributor continues to operate in a challenging environment characterized by thin margins and regulatory scrutiny.
Active Intelligence and Nutriband Inc. Showcases Expanding Ai Wellness Product Portfolio and Announces New June Product Launches At Ecrm Conference
Nutriband Inc. and its subsidiary, Active Intelligence, are set to showcase their expanded AI-branded product portfolio and announce new June product launches at the upcoming ECRM conference. The company plans to meet with major retailers and distributors to introduce new products like AI Performance Tape, AI Energy Patches, and AI Sleep, aiming to strengthen its position in the global wellness market. These new offerings are expected to broaden opportunities for national retail placement across multiple high-growth consumer categories.
Cardinal Health (CAH) Valuation Check As Income Drop And Goodwill Impairment Pressure The Story
Cardinal Health (CAH) is back in focus following a decline in net income and a significant goodwill impairment in its latest quarter, despite strong long-term shareholder returns and an increased dividend. The company's valuation is debated, with one narrative suggesting it is 24% undervalued at $245.27 per share, while its current P/E ratio of 28.1x is above the industry average, implying less margin of safety. Investors are urged to consider key rewards and warning signs to form their own view on the stock's future prospects.
CAH Stock Down Nearly 9.4% YTD: Should You Buy, Hold or Sell?
Cardinal Health (CAH) stock has declined 9.4% year-to-date but has outperformed its industry and peers due to strong operational performance. Key growth drivers include specialty drug demand, the Red Oak Generics Program, and operational efficiency, leading to positive earnings estimate revisions. Despite a premium valuation and some potential normalization of growth drivers, analysts view CAH as a compelling investment due to its strong earnings trajectory and favorable industry trends, giving it a Zacks Rank #2 (Buy).
Cardinal Health Inc. stock outperforms competitors on strong trading day
Cardinal Health Inc. (CAH) shares rose by 4.31% to $194.38 on Thursday, outperforming the broader market. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, rising 0.77% and 0.75% respectively. This marks the third consecutive day of gains for Cardinal Health stock.
Cardinal Health stock (US14149Y1082): Beats Q3 Earnings, Analysts Trim Price Targets
Cardinal Health reported strong Q3 fiscal 2026 earnings of $3.17 per share, exceeding consensus estimates by $0.38 due to growth in pharmaceuticals and specialty products. Despite this, analysts like Baird and Bank of America have trimmed price targets, citing peer valuation pressures. The stock maintains a "Moderate Buy" rating with significant upside potential, though its P/E ratio is higher than industry averages.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) stock is recommended for holding, primarily due to its strong fourth-quarter fiscal 2026 performance, growth in Health Savings Accounts (HSAs), and advancements in AI and digital innovation driving efficiency. The company demonstrated robust account growth and significant improvements in gross and operating margins. However, potential data security threats remain a key concern for the company.
Cardinal Health (CAH) Valuation Check As Income Drop And Goodwill Impairment Pressure The Story
Cardinal Health (CAH) is under investor scrutiny after its latest quarter revealed a year-over-year decline in net income and a significant goodwill impairment, despite strong pharmaceutical distribution sales and ongoing capital returns. While the stock has seen a recent dip, its long-term performance remains robust, prompting a reevaluation of its valuation. Current analysis suggests CAH might be undervalued according to one narrative, but its P/E ratio exceeding industry averages hints at potential overvaluation.
Cardinal Health Was Supposed to Beat UnitedHealth. Did It? Will It?
This article evaluates a year-old prediction that Cardinal Health (CAH) would be a safer healthcare stock than UnitedHealth (UNH). While UnitedHealth significantly outperformed Cardinal Health in total return over the past 12 months and recent momentum, analysts' forward views suggest Cardinal Health has greater implied upside and faster EPS growth. The author concludes that UnitedHealth is suitable for retirement investors seeking large scale and dividends, while Cardinal Health is better for those with a longer horizon and tolerance for near-term drawdowns, due to its higher analyst bullishness and implied upside.
Baird Keeps Outperform on Cardinal Health (CAH) Following Earnings Update
Baird has maintained its Outperform rating on Cardinal Health (CAH), despite lowering its price recommendation to $248 from $257, based on model updates after the company's first-quarter results and a raised 2027 forecast. BofA also reduced its price target to $240 from $260 but kept a Buy rating, noting Cardinal Health's mixed-to-positive fiscal Q3 results and increased fiscal 2026 EPS guidance. Cardinal Health raised its full-year fiscal 2026 non-GAAP EPS guidance to $10.70-$10.80 and adjusted free cash flow guidance to $3.3-$3.7 billion, while lowering its effective tax rate outlook.
Baird Keeps Outperform on Cardinal Health (CAH) Following Earnings Update
Baird has reaffirmed its 'Outperform' rating on Cardinal Health (CAH) following the company's first-quarter results, although it slightly lowered its price target from $257 to $248. This decision comes after Cardinal Health raised its fiscal 2026 EPS guidance and adjusted free cash flow outlook, partly due to a lower effective tax rate. The improved guidance is expected to address investor concerns regarding potential industry growth slowdowns.
Silexion begins clinical manufacturing of SIL204 for phase 2/3 trial
Silexion Therapeutics Corp. has started clinical manufacturing of SIL204, an siRNA therapy for pancreatic cancer, to support an upcoming Phase 2/3 clinical trial. This development follows approval from the Israeli Ministry of Health and the Helsinki Ethics Committee, targeting mutated KRAS oncogenes. Despite a significant stock decline over the past year, InvestingPro analysis suggests the stock is undervalued, holding more cash than debt, though the company is currently unprofitable and burns cash quickly.
Cardinal Health (CAH) Valuation Check As Income Drop And Goodwill Impairment Pressure The Story
Cardinal Health (CAH) is re-entering investor discussions following a recent quarter marked by a net income decline and significant goodwill impairment related to its Navista and ION units. Despite these challenges, the company posted strong pharmaceutical distribution sales and continued share repurchases, with an updated dividend. While the share price has seen a short-term dip, long-term returns remain robust, leading to questions about whether the stock is still undervalued or if future growth has already been priced in.
McKesson Corporation stock (US58155Q1031): Strong FY2026 results, raised guidance and $2.25B buyback
McKesson Corporation reported strong fiscal year 2026 results, with full-year revenues of $403.4 billion and adjusted EPS of $39.11, exceeding growth targets. The company also announced a $2.25 billion share repurchase program and raised its FY2027 adjusted EPS guidance, reflecting confidence in the U.S. healthcare market. McKesson's success is attributed to its dominant position in pharmaceutical distribution and diversified healthcare services.
Cardinal Health Inc stock (US14149Y1082): Recent earnings beat highlights strong performance
Cardinal Health Inc reported strong earnings for its last quarter, with $3.17 per share surpassing estimates of $2.80, demonstrating operational strength in its distribution and services. The company, a key player in pharmaceutical distribution, benefits from its dual-segment model covering drug distribution and medical products. Despite industry pressures from drug pricing reforms, Cardinal Health maintains a strong competitive position and offers US investors direct exposure to critical pharmaceutical supply chains.
Cardinal Health Inc. stock outperforms competitors on strong trading day
Cardinal Health Inc. (CAH) stock advanced by 2.08% to $186.35 on Wednesday, outperforming the S&P 500 Index which rose 0.58%, and the Dow Jones Industrial Average which fell 0.14%. This marks the second consecutive day of gains for the stock.
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
Cardinal Health's Pharmaceutical & Specialty Solutions segment is driving significant growth, with revenues climbing 19% and profit increasing 29% in Q3 fiscal 2026, primarily due to strong demand for specialty and branded products. The company anticipates specialty revenues to exceed $50 billion in fiscal 2026, supported by demographic trends and deepening partnerships. Competitors like McKesson and Cencora are also expanding their specialty segments, indicating a broader industry trend towards high-margin specialty pharmaceuticals.
Cencora (BIT:1COR) - Stock Analysis
This Simply Wall St analysis of Cencora (BIT:1COR) covers its valuation, future growth, past performance, financial health, dividends, management, and ownership. The report indicates Cencora is trading below its fair value with expected earnings growth and strong past performance, but notes a highly volatile share price and debt not well-covered by operating cash flow. Recent news highlights updated earnings guidance, quarterly dividend announcements, leadership changes, and significant acquisition activities.
Cardinal Health Extends Beyond Distribution With Surgical Case Cart Automation
Cardinal Health (NYSE:CAH) is expanding its involvement in the global surgical case carts market, indicating a strategic move into medical equipment and automation beyond its traditional distribution business. This shift aligns with trends in hospital automation, sterilization, and RFID tracking in surgical workflows. While investors have largely focused on financial results and distribution, the company's stock has seen significant gains, which may be partly driven by these new medical equipment activities.
